身处于全球经济一体化的关键阶段，阿根廷正在加强和中国以及欧盟这两个重要的贸易战略伙伴的合作。在2024年第四季度，阿根廷在重塑其商业和政治版图的方面取得了重要的成果，进一步推进了海外投资和贸易全球化。
第一项成果即2024年10月批准的《阿中避免双重征税协定》。该协定有助于两国消除财政的不确定性、优化成本并深化经济合作。
其次，经过二十多年的商讨，《欧盟-南共市自由贸易协定》的谈判也已告一段落。一旦该自贸协定落实，将促成大型自由贸易区的建立，为两个地区之间的贸易、政治和经济合作以及可持续发展带来强有力的支撑。
Continue reading “阿根廷正在不断加强与中国和欧盟的贸易合作”
SINGAPORE, Jan 6, 2025 – Selvam LLC is pleased to announce the promotion of Leonard Loh and Roshan Singh Chopra to Directors, effective January 2025. Both have demonstrated deep legal expertise and leadership within the firm.
Leonard is well-known for his handling of difficult and complex disputes, while Roshan’s recognition as a “Rising Star of 2024” by Asian Legal Business highlights his outstanding work in commercial litigation.
Continue reading “Selvam LLC 2025 Promotion Announcement”
2024年12月3日，美国德克萨斯东区联邦地区法院发布了一项初步禁令，为《公司透明度法案》（“CTA”）的执行按下了“暂停键”， 这一动态即刻引发在美企业的高度关注。该裁定暂时阻止了企业向美国金融犯罪执法网络（“FinCEN”）提交受益所有权信息(BOI)的要求，并将原定于2025年1月1日的合规期限搁置。
Continue reading “全美初步叫停《公司透明法》，这对申报企业有何影响?”
SINGAPORE, 5 November 2024 — Duane Morris & Selvam LLP acted as the U.S. counsel to ICICI Securities and Nomura Financial Advisory & Securities (India) in their role as the book running lead managers on the recent sale of approximately Rs. 12,000 million (US$143 million) of shares in Sansera Engineering Limited in a qualified institutions placement (QIP), including concurrent private placements outside India.
Continue reading “Duane Morris & Selvam Advises on the Sale of Rs. 12,000 million (US$143 million) Equity Shares in Sansera Engineering Limited in a QIP”
By Leon Yee and Sally Kim
On 4 October 2024, the Monetary Authority of Singapore (“MAS”) has published a consultation paper detailing the regulatory framework for Digital Token Service Providers (“DTSPs”) under the Financial Services and Markets Act 2022 (“FSM Act”). This framework addresses the licensing, anti-money laundering, countering the financing of terrorism (“AML/CFT”) requirements, and technological risk management for DTSPs, particularly those based in Singapore but offering services abroad.[1] To effect the objectives of Part 9 of the FSM Act, the MAS intends to prescribe or issue the following instruments: (a) the Financial Services and Markets Regulations (“FSM Regulations”); (b) AML/CFT notices under the FSMA; (c) other notices under the FSMA; and (d) guidelines.
Continue reading “Redefining Boundaries: MAS Consults on New Regulatory Framework for Digital Token Service Providers under the FSMA”
SINGAPORE, 1 October 2024 – Duane Morris & Selvam LLP recently acted as US counsel to Nuvama Wealth Management and Emkay Global Financial Services in their role as brokers to Proximus Opal on its divestment of a 6.03% stake in Route Mobile for approximately Rs, 6,213 million (US$74 million) through an Offer for Sale (OFS).
Continue reading “Duane Morris & Selvam Advises on the OFS of Shares in Route Mobile”
SINGAPORE, 10 September 2024 – Duane Morris & Selvam LLP acted as special international legal counsel to Equirus Capital Private Limited and IIFL Securities Limited in their role as the book running lead managers on the recent initial public offering of ₹6,012.00 million (USD 71.60 million) of equity shares of Ecos (India) Mobility & Hospitality Limited. Ecos is India’s largest and most profitable chauffeur driven mobility provider to corporates.
SINGAPORE, August 19, 2024 — Duane Morris & Selvam LLP is pleased to announce the appointment of Suilyn Yip as Head of Venture Capital. Suilyn, a distinguished partner in the firm’s full-service corporate practice, will bring her extensive expertise in corporate law to this pivotal role, further enhancing the firm’s venture capital practice and solidifying its position as a leading advisor in the sector.
Continue reading “Duane Morris & Selvam LLP Appoints Suilyn-Yip as Head of Venture Capital”
按照2024年1月1日生效的美国《公司透明度法案》（“CTA”）的要求，所有在美国注册成立和/或注册开展业务的美国和外国企业（包括某些信托公司）需向美国财政部下属的金融犯罪执法网络（“FinCEN”）提交报告，披露其拥有所有权或控制权的受益所有人的身份信息。CTA旨在防止罪犯、恐怖分子和腐败寡头在美国藏匿非法资金或其他财产。如果企业符合CTA中所列出的23项豁免条件之一，可免于申报。
近日，在Amarin Pharma诉Hikma Pharmaceuticals USA 案（编号2023-1169）中，美国联邦巡回法院推翻了特拉华州地区法院的裁决，认为Amarin的诉状合理地声称Hikma积极诱导了医疗服务提供者的直接侵权，不过同时还表示 “可能同意地区法院（和Hikma）”认为Hikma的缩减标签本身在法律上并没有推荐、鼓励或推动任何侵权使用。
